Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed connective tissue neoplasm, including any of the following neoplastic subtypes:~  * Vascular connective tissue neoplasms~ * Leiomyosarcoma~ * Dermatofibrosarcoma protuberans~ * Chordoma~ * Desmoid tumors~ * High-grade undifferentiated pleomorphic sarcoma (e.g., malignant fibrous histiocytoma \[including myxofibrosarcoma\])~ * Carcinosarcomas (e.g., malignant mixed Müllerian tumors)~ * Giant hemangiomata~ * Kaposi sarcoma~* Metastatic, locally advanced, or locally recurrent disease~* Measurable disease~  * Tumor lesions in a previously irradiated area may be considered measurable provided there is evidence of growth that cannot be attributed to necrosis or bleeding~* No gastrointestinal stromal tumor sarcomas~* Prior standard neoadjuvant or adjuvant systemic therapy required for patients with the following diagnoses:~  * Rhabdomyosarcoma~ * Osteosarcoma~ * Ewing sarcoma~* No untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as documented on screening CT scan or MRI~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 mg/dL~* PT and INR ≤ 1.5~* AST and ALT ≤ 2.5 times upper limit of normal~* Creatinine ≤ 1.5 mg/dL~* Calcium ≤ 12 mg/dL~* Blood glucose \< 150 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception prior to, during, and for 28 days after completion of study therapy~* Other malignancies allowed provided sarcoma is the primary disease requiring systemic therapy~* Able to swallow oral medications~* No other disease or illness within the past 6 months, including any of the following:~  * Myocardial infarction~ * Severe or unstable angina~ * Coronary or peripheral artery bypass graft~ * Symptomatic congestive heart failure~ * Cerebrovascular accident or transient ischemic attack~ * Pulmonary embolism~* No evidence of a bleeding diathesis~* No ongoing cardiac dysrhythmias \> grade 2~* No uncontrolled hypertension, defined as blood pressure \> 150/100 mm Hg despite optimal medical therapy~* Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan~* No psychiatric illness or social situation that would preclude study compliance~* No pre-existing thyroid abnormality, defined as abnormal thyroid function tests despite medication~* No prolonged QTc interval (i.e., QTc \> 450 msec for males or QTc \> 470 msec for females) on baseline EKG~* No hemorrhage ≥ grade 3 in the past 4 weeks~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* No prior sunitinib malate~* No more than 3 prior cytotoxic chemotherapy regimens for metastatic disease~  * Adjuvant chemotherapy for sarcoma completed \> 1 year prior to study entry is not considered a line of prior treatment~* At least 2 weeks since prior cytotoxic chemotherapy~* At least 6 weeks since prior carmustine or mitomycin C~* At least 1 week since prior biological therapy or small molecule kinase inhibitors~* At least 3 weeks since prior radiotherapy (except for palliative radiotherapy to specific sites)~  * Prior palliative radiotherapy allowed provided it is considered medically necessary and there are other target lesions to assess~* More than 4 weeks since prior major surgery~* Concurrent major surgery allowed provided study drug is stopped 2 weeks before surgery and resumed 2 weeks after surgery~* Concurrent palliative radiotherapy (e.g., focal radiotherapy to a bony metastasis for relieving bone pain) allowed~* No other concurrent investigational drugs~* No concurrent participation in another clinical trial~* No concurrent therapeutic anticoagulation (e.g., warfarin)~  * Prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial access devices allowed provided requirements for PT and INR are met~* No other concurrent approved or investigational anticancer agents or treatment, including chemotherapy, biological response modifier therapy, hormonal therapy, or immunotherapy~  * Concurrent hormone replacement therapy for adrenal insufficiency allowed~* No concurrent antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)~* No concurrent rifampin, theophylline, ketoconazole, or Hypericum perforatum (St. John's wort)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
- Group B (Type: EXPERIMENTAL): High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma \[MFH\]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
- Group C (Type: EXPERIMENTAL): Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).